ArticleArchives of osteoporosis2021
Insufficient persistence to pharmacotherapy in Japanese patients with osteoporosis: an analysis of the National Database of Health Insurance Claims and Specific Health Checkups in Japan.
Article in Archives of osteoporosis, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Evaluation of the fracture prevention effects of teriparatide and alendronate in patients with frailty: a sub-analysis of the Japanese osteoporosis intervention trial-05.Journal of bone and mineral metabolism · 2025Trial
- Repeated romosozumab with short-term ibandronate sequencing in high-risk osteoporosis: a retrospective single-center cohort study.JBMR plus · 2026Article
- Association of Polypharmacy and Bone Mineral Density: A Cross-Sectional Analysis of Geriatric Inpatients in Germany.Journal of clinical medicine · 2026Article
- International benchmarking of secondary fracture prevention in older adults with hip fracture: a Chinese hospital-based KPI audit.Frontiers in health services · 2026Article
- Cost-effectiveness of opportunistic osteoporosis screening using artificial-intelligence assisted chest radiographs in Japan.Osteoporosis and sarcopenia · 2025Article
- Bisphosphonate compliance in Japan from the perspective of product, formulation, and patient characteristics: analysis of medical insurance claim data.Journal of pharmaceutical health care and sciences · 2025Article
- A bibliometric analysis of the current state and future directions of osteoporosis pharmacological treatment.Frontiers in medicine · 2025Article
- The global burden of vertebral fractures caused by falls among individuals aged 55 and older, 1990 to 2021.PloS one · 2025Article
- Drug utilization pattern of romosozumab and other osteoporosis treatments in Japan, 2019-2021.Journal of bone and mineral metabolism · 2024Article
- Survey on Actual Management of Osteoporosis with the Japanese Medical Data Vision Database in Elderly Patients Undergoing Spinal Fusion.Journal of clinical medicine · 2024Article
- Global burden of hip fracture: The Global Burden of Disease Study.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2024Article
- Safety and effectiveness of once-yearly zoledronic acid in Japanese osteoporosis patients: three-year post-marketing surveillance.Journal of bone and mineral metabolism · 2023Observational
- Association between pharmacotherapy and secondary hip fracture in a real-world setting: a nationwide database study.Journal of bone and mineral metabolism · 2023Article
- Accuracy of the Fracture Risk Assessment Tool for judging pharmacotherapy initiation for primary osteoporosis.Journal of bone and mineral metabolism · 2022Article
- Population screening for fracture risk in postmenopausal women - a logical step in reducing the osteoporotic fracture burden?Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2022Article
- Medical expenditures for fragility hip fracture in Japan: a study using the nationwide health insurance claims database.Archives of osteoporosis · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In Japan, persistence and the 2-year MPR were inadequate in increasing fracture control efficacy despite a high adherence rate during the treatment period. Both factors were higher in females and those with polypharmacy but worsened with increasing age. PURPOSE: Only a few large-scale studies have examined the care gap between the patients who need osteoporosis treatment and those who receive them in Japan. The aim of this study was to investigate the persistence and adherence to osteoporosis pharmacotherapy in Japan.
methodsContinuation (persistence) rates and adherence to osteoporosis pharmacotherapy were investigated using medical insurance data from the National Database of Health Insurance Claims and Specific Health Checkups of Japan, between April 2012 and March 2019.
resultsThe study included 528,806 male and 3,064,410 female patients. Persistence proportions were 56.6% in the first year and 46.3% in the second year. The medication possession ratio (MPR) from start to discontinuation of treatment (MPR
conclusionIn Japan, persistence and the 2-year MPR were inadequate in increasing fracture control efficacy despite a high adherence rate during the treatment period. To bridge the care gap following osteoporosis pharmacotherapy, improvements are required for males, the elderly, and those without polypharmacy.
Indexed as
Identifiers
34515872What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.